Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4Shuang Qin, Suxia Luo|Molecular Cancer|2019Cited by 1.2k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trialSun Young Rha, Xiaochun Zhang, Min‐Hee Ryu et al.|The Lancet Oncology|2023Cited by 614